AtheroGenics
NASDAQ : AGIX

October 12, 2006 07:00 ET

AtheroGenics to Webcast Third Quarter Results Conference Call on October 24, 2006

ATLANTA, GA--(CCNMatthews - October 12, 2006) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its third quarter 2006 results of operations on Tuesday, October 24, 2006, before the U.S. financial markets open.

Company officials will provide a company update and discuss third quarter results via conference call and webcast on Tuesday, October 24, 2006, at 9:00 a.m. ET. The conference call may be accessed by dialing 1-877-407-8031 (domestic) or 1-201-689-8031 (international), five minutes prior to the start time. A replay of the call will be available from 11:00 a.m. ET on Tuesday, October 24, 2006, until 11:59 p.m. ET on October 31, 2006. Rebroadcast telephone numbers are 1-877-660-6853 (domestic) or 1-201-612-7415 (international), account number 286 and conference ID number 216271. To access the webcast, log on to the Company's Investor Relations Web site at http://www.atherogenics.com/investor/index.html. An archived version of this webcast will be available at the same location through January 25, 2007.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit www.atherogenics.com.


Contact Information